2. Academic Validation
  3. Refinement of imidazo[2,1-a]pyrimidines in pursuit of potential drug candidates against group 2 influenza A viruses

Refinement of imidazo[2,1-a]pyrimidines in pursuit of potential drug candidates against group 2 influenza A viruses

  • Eur J Med Chem. 2025 Aug 5:292:117679. doi: 10.1016/j.ejmech.2025.117679.
Malaika D Argade 1,  Varada Anirudhan 2,  Sean P Bradley 1,  Łukasz Tomorowicz 1,  Ryan Bott 2,  Boopathi Sownthirarajan 3,  Christian A Zielinski 1,  John P Sloan 4,  Dejan S Nikolic 1,  Arsen M Gaisin 1,  Terry W Moore 5,  Balaji Manicassamy 3,  Norton P Peet 6,  Lijun Rong 7,  Irina N Gaisina 8
Affiliations

Affiliations

  • 1 UICentre: Drug Discovery, University of Illinois Chicago, Chicago, IL, 60612, United States; Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, 60612, United States.
  • 2 Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, IL, 60612, United States.
  • 3 Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, 52242, United States.
  • 4 Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, 60612, United States.
  • 5 Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, 60612, United States; University of Illinois Cancer Center, Chicago, IL, 60612, United States.
  • 6 Chicago BioSolutions Inc., Chicago, IL, 60612, United States.
  • 7 Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, IL, 60612, United States; Chicago BioSolutions Inc., Chicago, IL, 60612, United States. Electronic address: lijun@uic.edu.
  • 8 UICentre: Drug Discovery, University of Illinois Chicago, Chicago, IL, 60612, United States; Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, 60612, United States; Chicago BioSolutions Inc., Chicago, IL, 60612, United States. Electronic address: igaysina@uic.edu.
PMID: 40318481 DOI: 10.1016/j.ejmech.2025.117679
Abstract

We discovered a series of imidazo[1,2-a]pyrimidines as potent, group 2 selective inhibitors of influenza A viruses (IAVs) that target the hemagglutinin-mediated viral entry process. Preliminary hit-to-lead optimization efforts afforded promising IAV inhibitors with improved activity against infectious H7N7 and H3N2 viruses. We now report a more comprehensive cycle of structure-activity relationship studies and optimization of metabolic stability, and overall druglike properties of this series of imidazo[1,2-a]pyrimidines, which allowed in the identification of two lead compounds that show promise as preclinical candidates. Compounds 10 and 12 inhibited pseudotyped H7N1 with EC50 values of 0.09 and 0.47 μM, respectively. They were among the most potent compounds in the viral replication assay when tested against infectious H3N2 IAV, and they also demonstrated remarkable activity against avian influenza viruses; these data designated these imidazo[1,2-a]pyrimidines as potent broad-spectrum group 2 IAV inhibitors. Compounds 10 and 12 exhibit dissimilar but desirable drug metabolism and pharmacokinetics (DMPK) profiles, and therefore they offer different options for specific and effective patient treatment.

Keywords

Anti-viral agent; Dimroth rearrangement; Imidazopyrimidines; Influenza A viruses.

Figures
Products